Hospital affiliation - see: www.rikshospitalet.no You may also visit: http://radium.no Academic position - see: www.med.uio.no/dnr

On this web site you will find information about my scientific work within cancer research,
as well as other activities.

Seksjonsoverlege Øyvind Bruland Onkologisk avd. Det Norske Radiumhospital N-0310 OSLO

Professor of Clinical Oncology Department of Medical Oncology & Radiotherapy The Norwegian Radium Hospital N-0310 Oslo, NORWAY

Tel. + 47 22 93 40 00 Dir. + 47 22 93 47 67 Fax. + 47 22 52 55 59 E-Mail: oyvind.bruland@medisin.uio.no

 

 

Recent publications

 

 

We compiled this book to shed light on several aspects of cancer - a disease that engenders more fear and uncertainty than most other prevalent diseases. In the popular science tradition, this book discusses causes and treatments of cancer, late effects that may develop after a cure is effected, some new inroads being made in cancer research, and we meet cancer patients and relatives in moving encounters that offer precious insight.

Click here for more information on this illustrated book, with its content, foreword, author biographies and a PDF of my own chapter: "Cancer - Causes and Treatment."

[19.02.08]

 

 

Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS.
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Lancet Oncol. 2007 Jul;8(7):587-94.

Download article in PDF format

  [05.11.07 10:10] 

 

 

Our group have recently published a translational study on alpha-particle based radiomimmunotherapy in the high-impact journal Blood
You may view a pdf of the paper here

  [19.11.07 13:49] 

 

 

Results from a Phase II randomized clinical trial of the novel alpha-emitting bone-seeker Alpharadin™ in patients with late-stage hormone-refractory prostate cancer (HRPC), including significant survival data, were presented at the American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium (Orlando, Florida, USA February 22-24, 2007).

You may view the poster here (Hyperlink to pdf)

  [26.02.07 13:30] 

 

 

In the latest issue of Clinical Cancer Research, a separate section is devoted to the proceedings from an expert meeting in Boston, October last year. Here invited papers on various aspects of the management of patients with bone metastases are published. This includes a review (by Bruland et al.) on external radiotherapy, bone-seeking radiopharamaceuticals, including recent progress using Alpharadin - a novel bone-seeker; currently in phase II clinical testing in patients with bone metastases from hormone refractory prostate cancer.

High-Linear EnergyTransfer IrradiationTargeted to Skeletal Metastases by the A-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? (PDF format)

Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference (PDF format)

  [26.10.06 12:10] 

 

 

Recently, we published results in "the green journal" form a randomised phase III clinical trial involving 376 patients with painful skeletal metastases form various malignancies. A comparison between a single dose (8Gy) and fractionated radiotherapy (3Gy x 10)revealed no major differences in the palliative benefit and shows that 8Gy x 1; with an option for re-treatment, should be standard management policy for these patients.

Click here to download the article (PDF format)

  [01.09.06 12:00]